GMO Beyond China ETFBCHI

BCHI is an exchange-traded fund listed on Nasdaq that promises exposure to Chinese equities “beyond the CSI 300,” a mandate designed to sound innovative while remaining comfortably inside the regulatory guardrails most offshore funds respect. The fund’s official structure is a Cayman Islands-incorporated RIC filing under Subchapter M, a classification that allows the vehicle to pass through income without US corporate taxation but does not change the fact that its holdings are the stocks the issuer selects, screens, and weights after reading the index provider’s fine print. The issuer’s marketing speaks of “GMO Beyond China,” a tag that implies a thematic edge, yet the portfolio is simply a basket of mainland A-shares, H-shares, and red-chips that the fund’s prospectus lists by name and weight but does not rebrand as genomic or disruptive. The fund’s expense ratio is 0.75%, a fee that looks modest until you remember the wrapper’s job is to own a portfolio someone else could buy directly in Shanghai or Shenzhen for a fraction of the cost.

The fund’s ticker, BCHI, is listed on Nasdaq under the equity ETF category, a venue that offers US-listed liquidity but does not guarantee tight spreads when Asian markets are open and New York is still digesting its lunch. On most days, average volume is below 12,000 shares, a figure that meets the fund’s stated liquidity needs but is thin enough to make block trades move the price by more than the issuer’s annual fee. The fund’s tracking error versus its stated benchmark is capped by prospectus language, yet the actual tracking error can widen when the manager’s discretion meets the index provider’s methodology clause, a tension the marketing rarely explains.

The fund’s regulatory filings are public on SEC EDGAR as part of N-1A registration number 333-28417, a document that reveals the fund’s domicile, filing status, and tax classification but does not list the holdings in real time or explain how the issuer translates “beyond the CSI 300” into actual stock weights. The issuer’s prospectus warns that the fund may hold ADRs, GDRs, and other structures to achieve its exposure, a concession that dilutes the pure “China” story while preserving the wrapper’s fee stream. FINRA’s Fund Analyzer confirms the fund’s regulatory status and fee schedule but does not audit the holdings, a limitation that matters when the marketing claims a thematic edge but the portfolio is just the index provider’s leftovers.

The Nasdaq market-activity page for BCHI shows daily price, volume, and NAV context, but it does not supply holdings, turnover, or tracking-error statistics; those details remain inside the issuer’s periodic reports, which are filed with the SEC but arrive with a lag that can exceed a month. The fund’s price can deviate from its NAV during volatile sessions, a spread that costs frequent traders less than the 0.75% headline fee but still feels like paying a premium for the convenience of a US-listed wrapper. The issuer’s marketing materials imply a high-conviction thematic portfolio, yet the actual portfolio is constrained by the index provider’s inclusion rules and the fund’s own concentration limits, which cap single-stock exposure and sector weights to comply with the RIC rules.

What changed this week is largely invisible to the public eye: the fund’s holdings and weights are updated quarterly, and the issuer’s website shows the latest fact sheet dated 2026-04-30, a document that lists the top ten positions and sector breakdown but does not reveal the fund’s tracking error or the identity of the index provider whose benchmark it claims to beat. The Nasdaq page refreshes price and volume in real time, but it does not reveal whether the fund is trading at a premium or discount to its NAV or whether the issuer has rebalanced the portfolio since the last fact sheet. In short, the market knows the ticker moves, the wrapper collects its fee, and the investor is left to trust the marketing while the data trickles in weeks late.